Arcturus Therapeutics Holdings (ARCT) Operating Expenses (2018 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Arcturus Therapeutics Holdings was $131.66 million, down 32.4% year-over-year; for FY2025, it came in at $158.29 million, down 36.2% from FY2024.

• Annual Operating Expenses shows a five-year compound annual growth rate of 14.3% (FY2020 to FY2025).
• In prior years, Arcturus Therapeutics Holdings' Operating Expenses was $247.98 million in FY2024 (+1.2%), $245 million in FY2023 (+26.4%), $193.82 million in FY2022 (-9.9%) and $215.21 million in FY2021 (+165.5%).
• The Q2 2026 figure stands as the lowest quarterly Operating Expenses since Q3 2020.
• On a year-over-year basis, Operating Expenses has declined in each of the last six quarters, with an average decline of 26.2% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2021, with growth of 141.8%; the weakest was Q2 2025, with a decline of 43.8%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $30.99 million (Q1 2026), $38.5 million (Q4 2025) and $33.66 million (Q3 2025).